Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (200)	5/17/2002 7:50:46 PM
From: scaram(o)uche	Respond to of 598

from the 10-K..... Virtual screening is the process by which computers calculate the theoretical binding affinity between a very large number of possible chemical structures and the active site of cellular receptors or enzymes for which the molecular structure has been solved. We added virtual screening to our capabilities in July 2001 with the acquisition of the computer-aided molecular design (CAMD) unit of Protherics PLC, now known as Tularik Ltd. Through this transaction, we acquired proprietary computational chemistry software and a team of experienced software designers, as well as computational chemists and medicinal chemists. The key aspect of the CAMD technology is a set of proprietary computational software tools that facilitate the identification of novel compounds. The use of virtual screening to complement our high-throughput screening capabilities may accelerate the discovery of high-quality leads against our validated targets. As part of the acquisition of the CAMD 14 -------------------------------------------------------------------------------- 13 2 Screening Library unit, we inherited a research collaboration with Eli Lilly relating to anti-thrombotics. The research portion of the Eli Lilly collaboration concluded in December 2001, however Eli Lilly is progressing a compound with activity against Factor Xa through its pre-clinical development process. In addition to the success milestone payment received in November 2001, we are entitled to additional payments for Factor Xa inhibitors as they progress through clinical trials to registration. Royalties are payable from Eli Lilly on sales of products emerging from the collaboration.

To: scaram(o)uche who wrote (200)	6/14/2002 1:41:15 PM
From: scaram(o)uche	Respond to of 598

more from Protherics, nothing here to chew on, but the paper itself is probably enlightening........ Curr Opin Drug Discov Devel 2002 May;5(3):407-13 Structure-based approaches to drug design and virtual screening. Waszkowycz B. Tularik Ltd, Beechfield House, Lyme Green Business Park, Macclefield, Cheshire, SK11 0JL, UK. bwaszkowycz@tularik.com Structure-based design has made an important contribution to drug discovery for many years. Recently, the increasing availability of structural data and the affordability of high-performance computing platforms have broadened the applicability of these methods. In particular, virtual screening has been adopted as an effective paradigm for lead discovery that fits in well alongside high-throughput screening programs. Structure-based virtual screening relies on fast and accurate computational methods for the prediction of receptor-ligand binding modes and binding affinities. In this paper, recent technical advances in the field of molecular docking and de novo design are reviewed, in particular, the development of flexible receptor models, docking of combinatorial libraries and novel scoring methods.